Telomerase targeted therapy in cancer and cancer stem cells

Clinical Advances in Hematology and Oncology

Volumn 9, Issue 6, 2011, Pages 442-455

  Xu, Yucheng ^a   He, Kaijie ^a   Goldkorn, Amir ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; ANTINEOPLASTIC AGENT; CANCER VACCINE; CAPECITABINE; GEMCITABINE; GRNVAC1; GUANINE QUADRUPLEX; IMETELSTAT; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NITROREDUCTASE; OBP 301; OLIGONUCLEOTIDE; QUARFLOXIN; TELOMELYSIN; TELOMERASE; TELOMERASE REVERSE TRANSCRIPTASE; TERTOMOTIDE; TRETAZICAR; TUMOR MARKER; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ADVANCED CANCER; ARTICLE; BLOOD CLOTTING DISORDER; BONE MARROW TOXICITY; BREAST CANCER; CANCER GENE THERAPY; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER STEM CELL; CANCER THERAPY; CARCINOGENESIS; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SUBPOPULATION; CHILL; CIRCULATING TUMOR CELL; CYTOPENIA; DISEASE ASSOCIATION; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; FATIGUE; FEVER; GASTROINTESTINAL SYMPTOM; GENE SILENCING; HUMAN; INJECTION SITE INFLAMMATION; INJECTION SITE PAIN; LIVER CELL CARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MELANOMA; METASTASIS; MOLECULARLY TARGETED THERAPY; MULTIPLE MYELOMA; MYELOMA; MYELOPROLIFERATIVE DISORDER; NEOPLASM; NEUTROPENIA; NONHUMAN; PAIN; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; SOLID TUMOR; TELOMERE; THROMBOCYTHEMIA; THROMBOCYTOPENIA; UPREGULATION;

ANIMALS; HUMANS; NEOPLASMS; NEOPLASTIC STEM CELLS; TELOMERASE;

EID: 79959966315     PISSN: 15430790     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (160)

1. Greider CW, Blackburn EH. Identifcation of a specifc telomere terminal transferase activity in Tetrahymena extracts. Cell. 1985;43:405-413.
2. de Lange T. Lasker Laurels for telomerase. Cell. 2006;126:1017-1020.
3. de Lange T I V, Blackburn EH. Telomeres. NY: Cold Spring Harbor Laboratory Press; 2005.
4. Grifth JD, Comeau L, Rosenfeld S, et al. Mammalian telomeres end in a large duplex loop. Cell. 1999;97:503-514.
5. Hastie ND, Dempster M, Dunlop MG, Tompson AM, Green DK, Allshire RC. Telomere reduction in human colorectal carcinoma and with ageing. Nature. 1990;346:866-868.
6. Verdun RE, Karlseder J. Replication and protection of telomeres. Nature. 2007;447:924-931.
7. Allsopp RC, Vaziri H, Patterson C, et al. Telomere length predicts replicative capacity of human fbroblasts. Proc Natl Acad Sci USA. 1992;89:10114-10118.
8. Smogorzewska A, de Lange T. Regulation of telomerase by telomeric proteins. Annu Rev Biochem. 2004;73:177-208.
9. Watson JD. Origin of concatemeric T7 DNA. Nat New Biol. 1972;239: 197-201.
10. Blackburn EH. Telomere states and cell fates. Nature. 2000;408:53-56.
11. Wright WE, Pereira-Smith OM, Shay JW. Reversible cellular senescence: implications for immortalization of normal human diploid fbroblasts. Mol Cell Biol. 1989;9:3088-3092.
12. de Lange T. Shelterin: the protein complex that shapes and safeguards human telomeres. Genes Dev. 2005;19:2100-2110.
13. Cesare AJ, Reddel RR. Alternative lengthening of telomeres: models, mechanisms and implications. Nat Rev Genet. 2010;11:319-330.
14. Cerone MA, Londono-Vallejo JA, Bacchetti S. Telomere maintenance by telomerase and by recombination can coexist in human cells. Hum Mol Genet. 2001;10:1945-1952.
15. Chen W, Xiao BK, Liu J P, Chen SM, Tao ZZ. Alternative lengthening of telomeres in hTERT-inhibited laryngeal cancer cells. Cancer Sci. 2010;101: 1769-1776.
16. Cohen SB, Graham ME, Lovrecz GO, Bache N, Robinson PJ, Reddel RR. Protein composition of catalytically active human telomerase from immortal cells. Science. 2007;315:1850-1853.
17. Greider C W, Blackburn EH. A telomeric sequence in the RNA of Tetra-hymena telomerase required for telomere repeat synthesis. Nature. 1989;337: 331-337.
18. Collins K. Physiological assembly and activity of human telomerase complexes. Mech Ageing Dev. 2008;129:91-98.
19. Collins K. The biogenesis and regulation of telomerase holoenzymes. Nat Rev Mol Cell Biol. 2006;7:484-494.
20. Egan ED, Collins K. Specificity and stoichiometry of subunit interactions in the human telomerase holoenzyme assembled in vivo. Molecular and Cellular Biology. 2010;30:2775-2786.
21. Venteicher AS, Abreu EB, Meng Z, et al. A human telomerase holoenzyme protein required for Cajal body localization and telomere synthesis. Science. 2009;323:644-648.
22. Mitchell JR, Wood E, Collins K. A telomerase component is defective in the human disease dyskeratosis congenita. Nature. 1999;402:551-555.
23. Kirwan M, Dokal I. Dyskeratosis congenita: a genetic disorder of many faces. Clin Genet. 2008;73:103-112.
24. Wright WE, Piatyszek MA, Rainey WE, Byrd W, Shay J W. Telomerase activity in human germline and embryonic tissues and cells. Dev Genet. 1996;18:173-179.
25. Forsyth NR, Wright WE, Shay J W. Telomerase and differentiation in mul-ticellular organisms: turn it of, turn it on, and turn it of again. Diferentiation. 2002;69:188-197.
26. Carey LA, Kim N W, Goodman S, et al. Telomerase activity and prognosis in primary breast cancers. J Clin Oncol. 1999;17:3075-3081.
27. Oishi T, Kigawa J, Minagawa Y, Shimada M, Takahashi M, Terakawa N. Alteration of telomerase activity associated with development and extension of epithelial ovarian cancer. Obstet Gynecol. 1998;91:568-571.
28. Okayasu I, Mitomi H, Yamashita K, et al. Telomerase activity signifcantly correlates with cell diferentiation, proliferation and lymph node metastasis in colorectal carcinomas. J Cancer Res Clin Oncol. 1998;124:444-449.
29. Pirker C, Holzmann K, Spiegl-Kreinecker S, et al. Chromosomal imbalances in primary and metastatic melanomas: over-representation of essential telomerase genes. Melanoma Res. 2003;13:483-492.
30. Poremba C, Heine B, Diallo R, et al. Telomerase as a prognostic marker in breast cancer: high-throughput tissue microarray analysis of hTERT and hTR. J Pathol. 2002;198:181-189.
31. Tomoda R, Seto M, Tsumuki H, et al. Telomerase activity and human telom-erase reverse transcriptase mRNA expression are correlated with clinical aggressiveness in soft tissue tumors. Cancer. 2002;95:1127-1133.
32. Yoshida R, Kiyozuka Y, Ichiyoshi H, et al. Change in telomerase activity during human colorectal carcinogenesis. Anticancer Res. 1999;19:2167-2172.
33. Hahn WC, Counter CM, Lundberg AS, Beijersbergen RL, Brooks MW, Weinberg RA. Creation of human tumour cells with defned genetic elements. Nature. 1999;400:464-468.
34. Hahn WC. Immortalization and transformation of human cells. Mol Cells. 2002;13:351-361.
35. Strahl C, Blackburn EH. Effects of reverse transcriptase inhibitors on telomere length and telomerase activity in two immortalized human cell lines. Mol Cell Biol. 1996;16:53-65.
36. Hahn WC, Stewart SA, Brooks MW, et al. Inhibition of telomerase limits the growth of human cancer cells. Nat Med. 1999;5:1164-1170.
37. Zhang X, Mar V, Zhou W, Harrington L, Robinson MO. Telomere shortening and apoptosis in telomerase-inhibited human tumor cells. Genes Dev. 1999;13:2388-2399.
38. Asai A, Oshima Y, Yamamoto Y, et al. A novel telomerase template antagonist (GRN163) as a potential anticancer agent. Cancer Res. 2003;63:3931-3939.
39. Dikmen ZG, Gellert GC, Jackson S, et al. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res. 2005;65:7866-7873.
40. Tamakawa RA, Fleisig HB, Wong JM. Telomerase inhibition potentiates the efects of genotoxic agents in breast and colorectal cancer cells in a cell cycle-specifc manner. Cancer Res. 2010;70:8684-8694.
41. Joseph I, Tressler R, Bassett E, et al. The telomerase inhibitor imetelstat depletes cancer stem cells in breast and pancreatic cancer cell lines. Cancer Res. 2010;70:9494-9504.
42. Kozlof M, Sledge G W, Benedetti FM, et al. Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC). J Clin Oncol (ASCO Annual Meeting Abstracts). 2010;28:Abstract 2598.
43. Ratain MJ, Benedetti FM, Janisch L, et al. A phase I trial of GRN163L (GRN), a frst-in-class telomerase inhibitor, in advanced solid tumors. J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26:Abstract 3581.
44. Herbert BS, Pongracz K, Shay J W, Gryaznov SM. Oligonucleotide N3'-P5' phosphoramidates as efcient telomerase inhibitors. Oncogene. 2002; 21:638-642.
45. Shammas MA, Koley H, Bertheau RC, et al. Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo. Leukemia. 2008;22:1410-1418.
46. Yu GL, Bradley JD, Attardi LD, Blackburn EH. In vivo alteration of telomere sequences and senescence caused by mutated Tetrahymena telomerase RNAs. Nature. 1990;344:126-132.
47. Kim MM, Rivera MA, Botchkina IL, Shalaby R, Tor AD, Blackburn EH. A low threshold level of expression of mutant-template telomerase RNA inhibits human tumor cell proliferation. Proc Natl Acad Sci U S A. 2001;98:7982-7987.
48. Guiducci C, Cerone MA, Bacchetti S. Expression of mutant telomerase in immortal telomerase-negative human cells results in cell cycle deregulation, nuclear and chromosomal abnormalities and rapid loss of viability. Oncogene. 2001;20:714-725.
49. Li S, Rosenberg JE, Donjacour AA, et al. Rapid inhibition of cancer cell growth induced by lentiviral delivery and expression of mutant-template telom-erase RNA and anti-telomerase short-interfering RNA. Cancer Res. 2004;64: 4833-4840.
50. Goldkorn A, Blackburn EH. Assembly of mutant-template telomerase RNA into catalytically active telomerase ribonucleoprotein that can act on telomeres is required for apoptosis and cell cycle arrest in human cancer cells. Cancer Res. 2006;66:5763-5771.
51. Marie-Egyptienne DT, Brault ME, Nimmo GA, Londono-Vallejo JA, Autexier C. Growth defects in mouse telomerase RNA-defcient cells expressing a template-mutated mouse telomerase RNA. Cancer Lett. 2009;275:266-276.
52. Xu T, Xu Y, Liao C P, Lau R, Goldkorn A. Reprogramming murine telomerase rapidly inhibits the growth of mouse cancer cells in vitro and in vivo. Mol Cancer Ter. 2010;9:438-449.
53. Stohr BA, Blackburn EH. ATM mediates cytotoxicity of a mutant telomerase RNA in human cancer cells. Cancer Res. 2008;68:5309-5317.
54. Xu T, Lu B, Tai YC, Goldkorn A. A cancer detection platform which measures telomerase activity from live circulating tumor cells captured on a microflter. Cancer Res. 2010;70:6420-6426.
55. Bravaccini S, Sanchini MA, Amadori A, et al. Potential of telomerase expression and activity in cervical specimens as a diagnostic tool. J Clin Pathol. 2005;58:911-914.
56. Hiyama E, Saeki T, Hiyama K, et al. Telomerase activity as a marker of breast carcinoma in fne-needle aspirated samples. Cancer. 2000;90:235-238.
57. Marchetti A, Bertacca G, Buttitta F, et al. Telomerase activity as a prognostic indicator in stage I non-small cell lung cancer. Clin Cancer Res. 1999;5:2077-2081.
58. Meeker AK. Telomeres and telomerase in prostatic intraepithelial neoplasia and prostate cancer biology. Urol Oncol. 2006;24:122-130.
59. Poremba C, Willenbring H, Hero B, et al. Telomerase activity distinguishes between neuroblastomas with good and poor prognosis. Ann Oncol. 1999;10: 715-721.
60. Shay JW, Bacchetti S. A survey of telomerase activity in human cancer. Eur J Cancer. 1997;33:787-791.
61. Streutker CJ, Torner P, Fabricius N, Weitzman S, Zielenska M. Telomer-ase activity as a prognostic factor in neuroblastomas. Pediatr Dev Pathol. 2001; 4:62-67.
62. Sanchini MA, Gunelli R, Nanni O, et al. Relevance of urine telomerase in the diagnosis of bladder cancer. JAMA. 2005;294:2052-2056.
63. Hiyama K, Ishioka S, Shay JW, et al. Telomerase activity as a novel marker of lung cancer and immune-associated lung diseases. Int J Mol Med. 1998;1:545-549.
64. Sen S, Reddy VG, Khanna N, Guleria R, Kapila K, Singh N. A comparative study of telomerase activity in sputum, bronchial washing and biopsy specimens of lung cancer. Lung Cancer. 2001;33:41-49.
65. Yahata N, Ohyashiki K, Ohyashiki JH, et al. Telomerase activity in lung cancer cells obtained from bronchial washings. J Natl Cancer Inst. 1998;90:684-690.
66. Targowski T, Jahnz-Rozyk K, Szkoda T, From S, Qandil N, Plusa T. Telomer-ase activity in transthoracic fne needle biopsy aspirates as a marker of peripheral lung cancer. Torax. 2008;63:342-344.
67. Iwao T, Hiyama E, Yokoyama T, et al. Telomerase activity for the preoperative diagnosis of pancreatic cancer. J Natl Cancer Inst. 1997;89:1621-1623.
68. Morales C P, Burdick JS, Saboorian MH, Wright WE, Shay JW. In situ hybridization for telomerase RNA in routine cytologic brushings for the diagnosis of pancreaticobiliary malignancies. Gastrointest Endosc. 1998;48:402-405.
69. Suehara N, Mizumoto K, Tanaka M, et al. Telomerase activity in pancreatic juice diferentiates ductal carcinoma from adenoma and pancreatitis. Clin Cancer Res. 1997;3:2479-2483.
70. Uehara H, Nakaizumi A, Iishi H, et al. In situ telomerase activity in pancreatic juice may discriminate pancreatic cancer from other pancreatic diseases. Pancreas. 2008;36:236-240.
71. Miura N, Maruyama S, Oyama K, et al. Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its signifcance as a tumor marker for hepatocellular carcinoma. Oncology. 2007;72 Suppl 1:45-51.
72. Da MX, Wu XT, Guo TK, et al. Clinical significance of telomerase activity in peritoneal lavage fuid from patients with gastric cancer and its relationship with cellular proliferation. World J Gastroenterol. 2007;13:3122-3127.
73. Clark GM, Osborne CK, Levitt D, Wu F, Kim NW. Telomerase activity and survival of patients with node-positive breast cancer. J Natl Cancer Inst. 1997;89:1874-1881.
74. Targowski T, Jahnz-Rozyk K, Szkoda T, Plusa T, From S. Telomerase activity in transthoracic fne-needle biopsy aspirates from non-small cell lung cancer as prognostic factor of patients' survival. Lung Cancer. 2008;61:97-103.
75. Hiyama E, Yokoyama T, Tatsumoto N, et al. Telomerase activity in gastric cancer. Cancer Res. 1995;55:3258-3262.
76. Tatsumoto N, Hiyama E, Murakami Y, et al. High telomerase activity is an independent prognostic indicator of poor outcome in colorectal cancer. Clin Cancer Res. 2000;6:2696-2701.
77. Soreide K, Gudlaugsson E, Skaland I, et al. Metachronous cancer development in patients with sporadic colorectal adenomas-multivariate risk model with independent and combined value of hTERT and survivin. Int J Colorectal Dis. 2008;23:389-400.
78. Hiyama E, Hiyama K, Yokoyama T, Matsuura Y, Piatyszek MA, Shay JW. Correlating telomerase activity levels with human neuroblastoma outcomes. Nat Med. 1995;1:249-255.
79. Soria JC, Gauthier LR, Raymond E, et al. Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients. Clin Cancer Res. 1999;5:971-975.
80. Fizazi K, Morat L, Chauveinc L, et al. High detection rate of circulating tumor cells in blood of patients with prostate cancer using telomerase activity. Ann Oncol. 2007;18:518-521.
81. FDA. 510(k) #K050245 premarket notifcation of intent to market device. March 15 2005.
82. Went PT, Lugli A, Meier S, et al. Frequent EpCam protein expression in human carcinomas. Hum Pathol. 2004;35:122-128.
83. Mani SA, Guo W, Liao MJ, et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell. 2008;133:704-715.
84. Cheng GZ, Chan J, Wang Q, Zhang W, Sun CD, Wang LH. Twist transcrip-tionally up-regulates AKT2 in breast cancer cells leading to increased migration, invasion, and resistance to paclitaxel. Cancer Res. 2007;67:1979-1987.
85. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9: 265-273.
86. Balzar M, Winter MJ, de Boer CJ, Litvinov SV. Te biology of the 17-1A antigen (Ep-CAM). J Mol Med. 1999;77:699-712.
87. Brunsvig P F, Aamdal S, Gjertsen MK, et al. Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer. Cancer Immunol Immunother. 2006;55:1553-1564.
88. Aamdal S, Dueland S, Engebraaten O, et al. A phase I/II study of telom-erase peptide vaccination in combination with chemotherapy in patients with stage IV malignant melanoma. J Clin Oncol (ASCO Annual Meeting Abstracts). 2006;24:Abstract 8031.
89. Greten T F, Forner A, Korangy F, et al. A phase II open label trial evaluating safety and efcacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma. BMC Cancer. 2010;10:209.
90. T. Buanes JM, W. Liauw, M. Hebbar, and J. Nemunaitis. A randomized phase III study of gemcitabine (G) versus GV1001 in sequential combination with G in patients with unresectable and metastatic pancreatic cancer (PC). J Clin Oncol (ASCO Annual Meeting Abstracts). 2009;27:Abstract 4601.
91. Vonderheide RH, Hahn WC, Schultze JL, Nadler LM. The telomerase catalytic subunit is a widely expressed tumor-associated antigen recognized by cyto-toxic T lymphocytes. Immunity. 1999;10:673-679.
92. Minev B, Hipp J, Firat H, Schmidt JD, Langlade-Demoyen P, Zanetti M. Cytotoxic T cell immunity against telomerase reverse transcriptase in humans. Proc Natl Acad Sci U S A. 2000;97:4796-4801.
93. Vonderheide RH, Domchek SM, Schultze JL, et al. Vaccination of cancer patients against telomerase induces functional antitumor CD8+ T lymphocytes. Clin Cancer Res. 2004;10:828-839.
94. Domchek SM, Recio A, Mick R, et al. Telomerase-specifc T-cell immunity in breast cancer: efect of vaccination on tumor immunosurveillance. Cancer Res. 2007;67:10546-10555.
95. Su Z, Dannull J, Yang BK, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specifc CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol. 2005;174:3798-3807.
96. Millard, F, Gerloni M, Darrah D, Monsurro V, Zanetti M. Phase I study of transgenic B lymphocyte immunization (TLI) against telomerase in andro-gen-independent prostate cancer (PC). J Clin Oncol (ASCO Annual Meeting Abstracts). 2005;23:Abstract 257.
97. Yi X, Shay J W, Wright WE. Quantitation of telomerase components and hTERT mRNA splicing patterns in immortal human cells. Nucleic Acids Res. 2001;29:4818-4825.
98. Irving J, Wang Z, Powell S, et al. Conditionally replicative adenovirus driven by the human telomerase promoter provides broad-spectrum antitumor activity without liver toxicity. Cancer Gene Ter. 2004;11:174-185.
99. Nemunaitis J, Tong AW, Nemunaitis M, et al. A phase I study of telomerase-specifc replication competent oncolytic adenovirus (telomelysin) for various solid tumors. Mol Ter. 2010;18:429-434.
100. Bilsland AE, Anderson CJ, Fletcher-Monaghan AJ, et al. Selective ablation of human cancer cells by telomerase-specifc adenoviral suicide gene therapy vectors expressing bacterial nitroreductase. Oncogene. 2003;22:370-380.
101. Smith F W, Feigon J. Quadruplex structure of Oxytricha telomeric DNA oligonucleotides. Nature. 1992;356:164-168.
102. Mikami-Terao Y, Akiyama M, Yuza Y, Yanagisawa T, Yamada O, Yamada H. Antitumor activity of G-quadruplex-interactive agent TMPyP4 in K562 leukemic cells. Cancer Lett. 2008;261:226-234.
103. Leonetti C, Scarsella M, Riggio G, et al. G-quadruplex ligand RHPS4 potentiates the antitumor activity of camptothecins in preclinical models of solid tumors. Clin Cancer Res. 2008;14:7284-7291.
104. Burger AM, Dai F, Schultes CM, et al. The G-quadruplex-interactive molecule BRACO-19 inhibits tumor growth, consistent with telomere targeting and interference with telomerase function. Cancer Res. 2005;65:1489-1496.
105. Gowan SM, Harrison JR, Patterson L, et al. A G-quadruplex-interactive potent small-molecule inhibitor of telomerase exhibiting in vitro and in vivo anti-tumor activity. Mol Pharmacol. 2002;61:1154-1162.
106. Waki K, Anno K, Ono T, Ide T, Chayama K, Tahara H. Establishment of functional telomerase immortalized human hepatocytes and a hepatic stellate cell line for telomere-targeting anticancer drug development. Cancer Sci. 2010;101:1678-1685.
107. Doi T, Shibata K, Yoshida M, et al. (S)-Stereoisomer of telomestatin as a potent G-quadruplex binder and telomerase inhibitor. Org Biomol Chem. 2011; 9:387-393.
108. Tahara H, Shin-Ya K, Seimiya H, Yamada H, Tsuruo T, Ide T. G-Quadruplex stabilization by telomestatin induces TRF2 protein dissociation from telomeres and anaphase bridge formation accompanied by loss of the 3' telomeric overhang in cancer cells. Oncogene. 2006;25:1955-1966.
109. Salvati E, Leonetti C, Rizzo A, et al. Telomere damage induced by the G-quadruplex ligand RHPS4 has an antitumor effect. J Clin Invest. 2007;117: 3236-3247.
110. Gomez D, Wenner T, Brassart B, et al. Telomestatin-induced telomere uncapping is modulated by POT1 through G-overhang extension in HT1080 human tumor cells. J Biol Chem. 2006;281:38721-38729.
111. Gomez D, O'Donohue MF, Wenner T, et al. The G-quadruplex ligand telo mestatin inhibits POT1 binding to telomeric sequences in vitro and induces GFP-POT1 dissociation from telomeres in human cells. Cancer Res. 2006;66: 6908-6912.
112. Siddiqui-Jain A, Grand CL, Bearss DJ, Hurley LH. Direct evidence for a G-quadruplex in a promoter region and its targeting with a small molecule to repress c-MYC transcription. Proc Natl Acad Sci U S A. 2002;99:11593-11598.
113. Sun D, Guo K, Rusche JJ, Hurley LH. Facilitation of a structural transition in the polypurine/polypyrimidine tract within the proximal promoter region of the human VEGF gene by the presence of potassium and G-quadruplex-interactive agents. Nucleic Acids Res. 2005;33:6070-6080.
114. Eddy J, Maizels N. Gene function correlates with potential for G4 DNA formation in the human genome. Nucleic Acids Res. 2006;34:3887-3896.
115. Drygin D, Siddiqui-Jain A, O'Brien S, et al. Anticancer activity of CX-3543: a direct inhibitor of rRNA biogenesis. Cancer Res. 2009;69:7653-7661.
116. Saretzki G, Sitte N, Merkel U, Wurm RE, von Zglinicki T. Telomere shortening triggers a p53-dependent cell cycle arrest via accumulation of G-rich single stranded DNA fragments. Oncogene. 1999;18:5148-5158.
117. Eller MS, Puri N, Hadshiew IM, Venna SS, Gilchrest BA. Induction of apoptosis by telomere 3' overhang-specifc DNA. Exp Cell Res. 2002;276:185-193.
118. Yaar M, Eller MS, Panova I, et al. Telomeric DNA induces apoptosis and senescence of human breast carcinoma cells. Breast Cancer Res. 2007;9:R13.
119. Aoki H, Iwado E, Eller MS, et al. Telomere 3' overhang-specifc DNA oli-gonucleotides induce autophagy in malignant glioma cells. FASEB J. Sep 2007; 21(11):2918-2930.
120. Puri N, Eller MS, Byers HR, Dykstra S, Kubera J, Gilchrest BA. Telo-mere-based DNA damage responses: a new approach to melanoma. FASEB J. 2004;18:1373-1381.
121. Tsolou A, Passos J F, Nelson G, Arai Y, Zglinicki T. ssDNA fragments induce cell senescence by telomere uncapping. Exp Gerontol. 2008;43:892-899.
122. Gangemi R, Paleari L, Orengo AM, et al. Cancer stem cells: a new paradigm for understanding tumor growth and progression and drug resistance. Curr Med Chem. 2009;16:1688-1703.
123. Akhtar K, Bussen W, Scott S P. Cancer stem cells - from initiation to elimination, how far have we reached? (Review). Int J Oncol. 2009;34:1491-1503.
124. Park CY, Tseng D, Weissman IL. Cancer stem cell-directed therapies: recent data from the laboratory and clinic. Mol Ter. 2009;17:219-230.
125. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755-768.
126. Gupta PB, Chafer CL, Weinberg RA. Cancer stem cells: mirage or reality? Nat Med. 2009;15:1010-1012.
127. O'Brien CA, Kreso A, Dick JE. Cancer stem cells in solid tumors: an overview. Semin Radiat Oncol. 2009;19:71-77.
128. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev Cancer. 2005;5:275-284.
129. Steiniger SC, Coppinger JA, Kruger JA, Yates J, Janda KD. Quantitative mass spectrometry identifes drug targets in cancer stem cell-containing side population. Stem Cells. 2008;26:3037-3046.
130. Chikazawa N, Tanaka H, Tasaka T, et al. Inhibition of Wnt signaling pathway decreases chemotherapy-resistant side-population colon cancer cells. Antican-cer Res. 2010;30:2041-2048.
131. Hu L, McArthur C, Jafe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. Br J Cancer. 2010;102:1276-1283.
132. Singh A, Wu H, Zhang P, Happel C, Ma J, Biswal S. Expression of ABCG2 (BCRP) is regulated by Nrf2 in cancer cells that confers side population and che-moresistance phenotype. Mol Cancer Ter. Aug 2010;9(8):2365-2376.
133. Reya T, Morrison SJ, Clarke M F, Weissman IL. Stem cells, cancer, and cancer stem cells. Nature. 2001;414:105-111.
134. Polyak K, Hahn WC. Roots and stems: stem cells in cancer. Nat Med. 2006;12:296-300.
135. Takahashi K, Tanabe K, Ohnuki M, et al. Induction of pluripotent stem cells from adult human fbroblasts by defned factors. Cell. 2007;131:861-872.
136. Yu J, Vodyanik MA, Smuga-Otto K, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917-1920.
137. Kelly PN, Dakic A, Adams JM, Nutt SL, Strasser A. Tumor growth need not be driven by rare cancer stem cells. Science. 2007;317:337.
138. Quintana E, Shackleton M, Sabel MS, Fullen DR, Johnson TM, Morrison SJ. Efcient tumour formation by single human melanoma cells. Nature. 2008;456:593-598.
139. Shmelkov SV, Butler JM, Hooper AT, et al. CD133 expression is not restricted to stem cells, and both CD133+ and CD133- metastatic colon cancer cells initiate tumors. J Clin Invest. 2008;118:2111-2120.
140. Sharma SV, Lee DY, Li B, et al. A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell. 2010;141:69-80.
141. Roesch A, Fukunaga-Kalabis M, Schmidt EC, et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell. 2010;141:583-594.
142. He K, Xu T, Goldkorn A. Cancer cells cyclically lose and regain a drug-resistant highly-tumorigenic phenotype in culture and in tumor xenografts. Mol Cancer Ter. 2011 Apr 25. [Epub ahead of print]
143. Maitland NJ, Collins AT. Prostate cancer stem cells: a new target for therapy. J Clin Oncol. 2008;26:2862-2870.
144. Bodnar AG, Ouellette M, Frolkis M, et al. Extension of life-span by introduction of telomerase into normal human cells. Science. 1998;279:349-352.
145. Lee HW, Blasco MA, Gottlieb GJ, Horner JW, Greider CW, de Pinho RA. Essential role of mouse telomerase in highly proliferative organs. Nature. 1998;392:569-574.
146. Sarin KY, Cheung P, Gilison D, et al. Conditional telomerase induction causes proliferation of hair follicle stem cells. Nature. 2005;436:1048-1052.
147. Gu G, Yuan J, Wills M, Kasper S. Prostate cancer cells with stem cell characteristics reconstitute the original human tumor in vivo. Cancer Res. 2007;67: 4807-4815.
148. Stewart SA, Hahn WC, O'Connor B F, et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc Natl Acad Sci USA. 2002;99:12606-12611.
149. Xu T, He K, Wang L, Goldkorn A. Prostate tumor cells with cancer progenitor properties have high telomerase activity and are rapidly killed by telomerase interference. Prostate. 2011 Feb 14. [Epub ahead of print]
150. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res. 2007;67:4827-4833.
151. Lin T, Meng L, Li Y, Tsai RY. Tumor-initiating function of nucleostemin-enriched mammary tumor cells. Cancer Res. 2010;70:9444-9452.
152. Marian CO, Cho SK, McEllin BM, et al. Te telomerase antagonist, ime-telstat, efciently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res. 2010;16:154-163.
153. Marian CO, Wright WE, Shay JW. The efects of telomerase inhibition on prostate tumor-initiating cells. Int J Cancer. 2010;127:321-331.
154. Ratain MJ, Benedetti FM, Janisch L, et al. A phase I trial of GRN163L (GRN), a frst-in-class telomerase inhibitor, in advanced solid tumors. J Clin Oncol (ASCO Annual Meeting Abstracts). 2008;26:Abstract 3581.
155. Parkhurst MR, Riley J P, Igarashi T, Li Y, Robbins P F, Rosenberg SA. Immunization of patients with the hTERT:540-548 peptide induces peptide-reactive T lymphocytes that do not recognize tumors endogenously expressing telomerase. Clin Cancer Res. 2004;10:4688-4698.
156. Rapoport A P, Aqui NA, Stadtmauer EA, et al. Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination based on hTERT and survivin following ASCT for myeloma. Blood. 2011;3:788-797.
157. Rech AJ, Mick R, Recio A, et al. Phase I study of anti-CD25 mab dacli-zumab to deplete regulatory T cells prior to telomerase/survivin peptide vaccination in patients (pts) with metastatic breast cancer (MBC). J Clin Oncol (ASCO Annual Meeting Abstracts). 2010;28:Abstract 2508.
158. Trepiakas R, Berntsen A, Hadrup SR, et al. Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial. Cytotherapy. 2010;12:721-734.
159. Berntsen A, Geertsen P, Trepiakas R, et al. Dendritic cell based vaccination in combination with IL-2 as a treatment for advanced renal cell carcinoma patients: results from a phase I/II trial. J Clin Oncol (ASCO Annual Meeting Abstracts). 2006;24:Abstract 2575.
160. Su Z, Dannull J, Yang BK, et al. Telomerase mRNA-transfected dendritic cells stimulate antigen-specifc CD8+ and CD4+ T cell responses in patients with metastatic prostate cancer. J Immunol. 2005;174:3798-3807.